Lv51
1460 积分 2023-07-24 加入
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
4天前
已完结
Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
4天前
已完结
Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management
1个月前
已完结
High HPK1+PD-1+TIM-3+CD8+ T cells infiltration predicts poor prognosis to immunotherapy in NSCLC patients
1个月前
已完结
UPCRISPR: an ultrafast, one-tube multiplexed nucleic acid detection system for resolving the diagnostic gray zone in HPV16/18 detection
2个月前
已完结
Emerging Trends in cervical cancer Treatment: Transitioning from traditional to innovative delivery strategies
2个月前
已完结
Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study
2个月前
已关闭
Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation
2个月前
已完结
Regulatory T cells in cardiac allograft vasculopathy: from mechanistic insights to clinical tolerance
3个月前
已完结
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
3个月前
已完结